|
See related Prezista film-coated tab information |
|
|
|
Manufacturer |
Janssen-Cilag |
|
Distributor |
DKSH |
|
Contents |
Darunavir |
|
Indications |
Treatment of HIV infection in antiretroviral treatment-experienced adults in combination w/ ritonavir & other antiretroviral agents.
Click to view Prezista detailed prescribing infomation |
|
Dosage |
Adult 600 mg bid w/ ritonavir 100 mg bid.
Click to view Prezista detailed prescribing infomation |
|
Overdosage |
View Prezista overdosage for action to be taken in the event of an overdose. |
|
Administration |
Should be taken with food |
|
Contraindications |
Hypersensitivity. Concomitant astemizole, terfenadine, midazolam, triazolam, cisapride, pimozide & ergot alkaloids (eg ergotamine, dihydroergotamine, ergonovine & methylergonovine).
Click to view Prezista detailed prescribing infomation |
|
Special Precautions |
Patients w/ sulfonamide allergy, severe hepatic impairment, chronic active hepatitis B or C, haemophilia. May exacerbate DM & hyperglycemia. Fat redistribution & metabolic disorders. Immune reactivation syndrome. Concomitant CYP3A inhibitors/inducers. May impair ability to drive or operate machinery. Pregnancy & lactation. Childn & adolescent (12-17 yr). Elderly.
Click to view Prezista detailed prescribing infomation |
|
Adverse Drug Reactions |
Diarrhoea, headache, abdominal pain, nausea, vomiting; increased hepatic & pancreatic enzymes, hypertriglyceridaemia, hypercholesterolaemia.
View ADR Monitoring Form |
|
Drug Interactions |
Rifampicin, St. John's wort, PIs (lopinavir, saquinavir, indinavir), antiarrhythmics, digoxin, warfarin, phenobarb & phenytoin, Ca channel blockers, clarithromycin, systemic dexamethasone, inhaled fluticasone propionate, HMG-CoA reductase inhibitors (eg lovastatin, simvastatin), immunossupressants (cyclosporin, tacrolimus, sirolimus), ketoconazole, itraconazole, voriconazole, methadone, estrogen-based contraceptives, PDE-5 inhibitors, rifabutin, SSRIs.
View more drug interactions with Prezista |
|
Pregnancy Category (US FDA) |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
Storage |
View Prezista storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Prezista description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Prezista mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
